comparison of glp-1 agonists short-acting versus long-acting receptor Closest medical alternatives to tirzepatide:
Description
Motility and Metabolic Pharmacoepidemiology Group, Ma KS, et al

This study tested one potent GLP-1 receptor agonist against another that is less potent but still showed an overall reduction in events, she says

This shift in endpoints reflects a broader reframing of obesity as a chronic disease rather than a lifestyle issue

Ozempic and Wegovy are proven to significantly lower those risks

Diab Care 42 , 507513 (2019)

Another exciting avenue is the development of small-molecule GLP-1RAs, designed for oral delivery
